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TAC-seq: targeted DNA and RNA sequencing for precise
biomarker molecule counting
Hindrek Teder 1,2, Mariann Koel1,3, Priit Paluoja 1,4, Tatjana Jatsenko1, Kadri Rekker1,5, Triin Laisk-Podar1,5,6, Viktorija Kukuškina6,
Agne Velthut-Meikas1,7, Olga Fjodorova3, Maire Peters1,5, Juha Kere8,9,10, Andres Salumets1,5,11,12, Priit Palta6,13 and Kaarel Krjutškov1,8,9
Targeted next-generation sequencing (NGS) methods have become essential in medical research and diagnostics. In addition to
NGS sensitivity and high-throughput capacity, precise biomolecule counting based on unique molecular identifier (UMI) has
potential to increase biomolecule detection accuracy. Although UMIs are widely used in basic research its introduction to clinical
assays is still in progress. Here, we present a robust and cost-effective TAC-seq (Targeted Allele Counting by sequencing) method
that uses UMIs to estimate the original molecule counts of mRNAs, microRNAs, and cell-free DNA. We applied TAC-seq in three
different clinical applications and compared the results with standard NGS. RNA samples extracted from human endometrial
biopsies were analyzed using previously described 57 mRNA-based receptivity biomarkers and 49 selected microRNAs at different
expression levels. Cell-free DNA aneuploidy testing was based on cell line (47,XX, +21) genomic DNA. TAC-seq mRNA profiling
showed identical clustering results to transcriptome RNA sequencing, and microRNA detection demonstrated significant reduction
in amplification bias, allowing to determine minor expression changes between different samples that remained undetermined by
standard NGS. The mimicking experiment for cell-free DNA fetal aneuploidy analysis showed that TAC-seq can be applied to count
highly fragmented DNA, detecting significant (p= 7.6 × 10−4) excess of chromosome 21 molecules at 10% fetal fraction level. Based
on three proof-of-principle applications we demonstrate that TAC-seq is an accurate and highly potential biomarker profiling
method for advanced medical research and diagnostics.
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INTRODUCTION
Physiological and pathophysiological disease conditions can be
often characterized by the precise quantification of specific
nucleic acid biomarkers. There are several methods available
enabling detection of RNA- or DNA-based biomarkers but recently,
next-generation sequencing (NGS) has become one of the favorite
approaches because of its high sensitivity, high-throughput, and
flexibility. However, despite of its advantages, the relatively high
cost of NGS limits its wider application in healthcare. In addition,
common NGS assays consist of multiple laboratory steps that
often introduce technical biases limiting accurate quantification
and, therefore, hinder the robust and clinically valid detection of
biomarkers.1–3 Although quantitative PCR and digital PCR provide
simple and cost-effective alternatives to NGS for quantitative
biomarker determination, the multiplexing capacity of these
approaches is limited compared to highly parallel NGS-based
methods.
To overcome the challenges of precise target quantification on
extended scale, NGS sensitivity together with high specificity of
ligation-PCR have been compiled into common methods and
assays. For example, NGS- and ligation-based TempO-Seq4
(Templated Oligo assay with Sequencing readout) and MLPA-
seq5 are advancement of the well-known MLPA6 (Multiplex
Ligation-dependent Probe Amplification). Both methods over-
come original MLPA multiplexing and detection limitations, and
enable to apply sensitivity of NGS and analyze up to 20,000 RNA
and 200 genomic DNA (gDNA) targets, respectively. Similar
approaches are also RASL-seq7 for targeted multiplex messenger
RNA (mRNA) analysis and another NGS and targeted ligation-PCR-
based method DANSR (digital analysis of selected regions) for cell-
free DNA (cfDNA) detection in non-invasive prenatal genetic
testing (NIPT). The authors of the latter method report that 384
loci per chromosome 18 and chromosome 21 (altogether 768 loci
in a single-tube reaction) are sufficient for aneuploidy discrimina-
tion, which makes it significantly less complex assay than so far
widely used low-coverage whole-genome sequencing for NIPT.8
However, the strategy where ligation-PCR is combined with NGS
ensures high level of multiplexing but suffers from the random
ligation at low target nucleic acid levels, and on the polymerase-
induced errors in both PCR and sequencing steps.9–11 As an
outcome, above highlighted methods overestimate the original
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number of studied molecules and are biased by PCR uneven
amplification.
To overcome amplification bias in NGS and to maximize nucleic
acid detection sensitivity, unique molecular identifiers (UMIs,
known also as molecular indexes, unique identifiers or molecular
barcodes) are applied. UMI is a string of random nucleotides used
in library preparation that was recently introduced to genomic
DNA analysis12 and also in single-cell transcriptome analysis.13
One specific motif out of a large pool of random sequences is
incorporated into the original target molecule through oligonu-
cleotides used in library preparation prior to amplification. Later,
grouping by identical UMI clones eliminates PCR duplicates and
detects the original number of biomolecules. So far, UMIs are
widely used in research applications where relatively high PCR
amplification is required, such as single-cell analysis and tumor
mutation identification.13–17 Similarly to above-mentioned appli-
cations, UMIs can also be used in targeted ligation-PCR NGS assays
to enable absolute quantification of studied biomarker molecules.
Taking the previous into account, we developed a ligation- and
NGS-based method, TAC-seq, targeted allele counting by sequen-
cing method for original molecule counting of plasma cfDNA and
RNA-based biomarkers.
RESULTS
TAC-seq principle and assay design
TAC-seq is a single-tube and ligation-based assay that allows
precise biomarker quantification by the use of two UMI sequences
in detector oligonucleotide probes. The studied mRNA and cfDNA
molecules are uniquely identified using 54-bp-long target
complementary sequence that is detected by two side-by-side
located TAC-seq probes (Fig. 1a). Once stringent hybridization of
the detector probes to the target occurs, a thermostable ligase is
introduced, catalyzing the formation of a phosphodiester bond
between the 5′-phosphate and the 3′-hydroxyl of two side-by-side
detector probes. Next, ligated detector-target complexes are
captured using magnetic beads and amplified by PCR (Supple-
mentary Fig. 1), resulting in a ready-to-sequence library within a
3 h turnaround time. The risk of losing studied biomolecule is
minimized by the dilution-free protocol in which ligated detector
probes are captured, amplified, and identified by sequencing. To
simplify the in silico design of specific TAC-seq probes and data
analysis, we developed an online tool for designing the TAC-seq
probes (http://nipt.ut.ee/design/) and a computational workflow
software to enable data processing (open-source software link is
in Methods and principle shown in Supplementary Fig. 2).
Experimental evaluation of TAC-seq
First, we used External RNA Controls Consortium (ERCC) RNA
spike-in controls to validate the technical sensitivity and accuracy
of the TAC-seq method. Altogether, 22 spike-in sequences were
assayed at various concentrations, ranging from 1 to 3 × 105
molecules per reaction (Supplementary Table 1). The spike-in
sequences were then detected with TAC-seq probes, sequenced
and counted at different UMI thresholds. The analysis consistently
demonstrated a high correlation (Spearman r > 0.99, Fig. 1b–c)
between input and detected molecules for both relaxed and
conservative (n > 1 molecules required) UMI thresholds.18 These
results suggested that conservative UMI thresholds (n ≥ 3 mole-
cules required in this case, Fig. 1c) are justified and applicable for
high-coverage sequencing, in which the unfiltered read numbers
are significantly higher than the UMI corrected outcome.18 With
seven technical ERCC replicates, the average 1.5 × 106 raw read-
count per replicate dropped to 5.7 × 103 after UMI correction,
demonstrating a 102-fold average PCR redundancy at UMI
threshold of 4 (n= 4) (Supplementary Table 1). Additionally,
excellent reproducibility (Spearman r= 0.9915, Fig. 1d) among
seven ERCC replicates was demonstrated.
mRNA detection—precise molecule counting of endometrial
receptivity biomarkers
Next, we designed a transcriptome assay to analyze human
endometrial linings. We targeted 57 endometrial receptivity mRNA
transcripts that are potential biomarkers in reproductive medicine
for testing embryo implantation compatibility.19 Ten endometrial
biopsy samples were analyzed by TAC-seq and compared with the
levels of selected 57 transcripts from full transcriptome RNA
sequencing (RNA-seq) data. Principal component analysis of these
data showed identical clustering of samples when applied to RNA-
seq results and two different TAC-seq assays, carried out with
high- (denoted as TAC-seqhigh, average 25.7 × 10
6 reads per
sample) and low-coverage (TAC-seqlow, average 1.23 × 10
6 reads
per sample) sequencing (Fig. 2a). In these analyses, the first
component described most of the sample variability (RNA-seq
89.8%, TAC-seqhigh 79.6%, TAC-seqlow 83.0%) and distinguished
the pre-receptive and receptive samples (n= 5 in both the groups,
Fig. 2a), except for one outlier sample both in RNA-seq and TAC-
seq analyses. The same sample grouping was confirmed by
hierarchical clustering: four pre-receptive samples clustered
together with high confidence (approximately unbiased (AU)
probability of 100%), and receptive samples clustered together
with one outlier sample in all datasets (AURNA= 94%; AUTAC-high=
69%; AUTAC-low= 81%) (Fig. 2b and Supplementary Fig. 3).
In both high- and low-coverage TAC-seq approaches all 57
differentially expressed transcripts were detected. However, high-
coverage sequencing analysis revealed that 8-bp UMI causes
technical limitation in molecule detection in the upper detection
range. Six highly expressed genes met UMI-related saturation and
were not precisely quantified (Supplementary Fig. 4). This
technical limitation can be easily overcome by adding longer
UMI nucleotides to detector oligonucleotides or by sequencing
with lower coverage.
In low-coverage assay we expanded the assay to a 70-plex by
adding housekeeping genes (n= 8) and selected ERCC spike-ins
(n= 5). We observed that although the assayed housekeeping
genes represented 47.4% of all unique reads in this assay, the
biomarker-based clustering probability was still high (AUTAC-low=
81%) and all of the targeted 57 biomarkers were detected (Fig.
2b). Based on these results, we suggest to include housekeeper
genes (e.g., CYC1, HMBS, SDHA, and TBP) with low or moderate
expression to low-coverage TAC-seq endometrium assay to ensure
enough sequencing reads for all studied receptivity biomarkers.
microRNA detection—differentially expressed molecules in
endometrium
To test the feasibility of TAC-seq with small non-coding microRNAs
(miRNA), we selected 49 miRNAs from endometrial tissue, which
were previously analyzed by small RNA-seq and covered highly
variable expression levels from 10 to 4,712 counts per million.
TAC-seq detected all 49 assayed miRNAs over 16 analyzed
endometrial samples with high reproducibility (Spearman r >
0.997, Fig. 3) and showed high sensitivity in order to distinguish
biologically different pre-receptive and receptive clinical biopsies
in unsupervised clustering that were not detected by previous
RNA-seq assay (Supplementary Fig. 5).
Due to the nature of miRNAs, short 20–24-bp target regions
were detected using specific probes, and the TAC-seq protocol
was modified accordingly (Supplementary Fig. 6). Additionally, an
in silico prediction based on RNA-seq suggested that the selected
set of miRNAs had nucleotide imbalance20 at positions one (G <
2%) and five (C < 3%), causing potential sequencing failure
(Supplementary Fig. 7). The limitation was overcome using an
adjusted spike-in probe that was designed to compensate for the
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two less-represented nucleotides at certain positions and there-
fore balance the whole sequencing run. The custom spike-in was
later added to the sequencing reaction, resulting in a balanced
nucleotide distribution and a high, 96% pass-filtering read rate
(Supplementary Fig. 8). Although RNA-seq is convenient for
miRNA profiling, our results confirm the previous findings21 that
amplification bias reduction using UMI can enhance sensitivity. As
a result, TAC-seq separates biologically different samples even in
case of minor expression differences (Supplementary Fig. 5).
Cell-free DNA detection—trisomy detection using controlled
conditions
As the last test, we evaluated the potential of the TAC-seq method
for NIPT, a widely used NGS-based clinical application. NIPT
Fig. 1 Principle and technical parameters of TAC-seq. a Schematic diagram of the assay to detect specific mRNA or cell-free DNA. Target-
specific DNA oligonucleotide detector probes hybridize under stringent conditions to the studied cDNA or cfDNA. Both detector
oligonucleotides consist of a specific 27-bp region (green), 4-bp unique molecular identifier (UMI) motif (NNNN), and universal sequences
(purple and orange). The right detector oligonucleotide is 5′ phosphorylated. After rigorous hybridization, the pair of detector probes is
ligated using a thermostable ligase under stringent conditions. Next, the ligated detectors complexed with the target region are captured
with magnetic beads and PCR amplified to introduce sample-specific barcodes and other common motifs that are required for single-read
NGS. b Spearman correlation analysis of the input and detected ERCC synthetic spike-in mRNA molecules at UMI threshold 4 (UMI= 4). UMI
threshold is defined as the number of detected unique UMI sequences. For example, UMI= 4 indicates that a certain UMI motif is detected at
least four times. UMIs are valuable only if the number of UMI combinations (8-bp UMI provides 65,536 variants, for example) is substantially
larger than the sum of the target molecules in the studied sample. c Bar plot of Spearman’s correlation analysis of the ERCC input and
detected molecules at different UMI thresholds. d Reproducibility of seven technical ERCC replicates (seven different icons on plot) of 22
spike-in molecules at UMI= 4
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detects fetal trisomy based on the molecular counting of fetal
cfDNA in maternal blood samples. We designed a proof-of-
principle trisomy 21 detection assay to demonstrate the applic-
ability of the TAC-seq method for absolute cfDNA molecule
counting to determine fetal trisomy at different experimentally
controlled ‘‘fetal fraction’’ levels. In the following in vitro
aneuploidy detection experiment, we mixed different proportions
of gDNA from a chr21 trisomy cell line with a known normal
control gDNA. Different proportions of fetal trisomic cfDNA were
created to imitate the range of fetal fraction in mothers’
circulating cfDNA. gDNAs were sheared by sonication to mimic
160–180 bp cfDNA, mixed to yield 5–30% trisomy proportions and
hybridized with TAC-seq detector probes that were designed to
target reference chromosomes (chr2 and chr3) and studied chr21.
The detection of trisomy 21 demonstrated a significant
difference at the lowest 10% ‘‘fetal cfDNA fraction’’ (Fig. 4), which
H. Teder et al.
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improved even further in case of every additional 5% increase in
the ‘‘fetal fraction.’’ The same result was confirmed by whole-
genome re-sequencing NIPT assay for the same samples22
(Supplementary Fig. 9). Replication TAC-seq experiment with
extended probe set demonstrated significant (p= 7.6 × 10−4)
excess of chromosome 21 molecules at 10% fetal fraction level,
applying UMI= 2 threshold (Fig. 4).
DISCUSSION
Combining high sensitivity and flexibility of NGS with cost-
efficient and precise quantification of targeted methods can
enable robust detection of specific nucleic acid biomarkers
indicative of (patho)physiological conditions. TAC-seq is an
advanced ligation-based NGS method that differs from existing
ligation-PCR assays such as MLPA6, MLPA-seq5, TempO-Seq4,
RASL-seq7 and DANSR.8 The major advantage of TAC-seq is ability
to detect the number of original molecules of transcriptomic
biomarkers such as mRNA and miRNA, and genomic loci from
cfDNA. Precise molecule counting is achieved by integrated UMI
or ‘‘molecular barcode’’ motif12, which decreases the quantitative
and random bias introduced by in vitro replication steps. Using
UMIs removes PCR duplicates, reducing one of the major NGS-
specific technical biases and improves the accuracy of NGS.
We detected very high sensitivity correlation over 22 analyzed
ERCC spike-in input and detected molecules (Spearman r= 0.9958
on Fig. 1d) with high-coverage, ensuring that each UMI coverage
was 102×. Based on the coverage, we are confident that very few
UMIs have been missed and, therefore, this outcome is reliable.
However, systematic difference appears between lowly- and
highly expressed targets with the number of high copy-number
molecules is underestimated (see top-four ERCC spike-ins in
Supplementary Table 1). This is explained by the length of UMI
sequences, causing ‘‘technical saturation.’’ Eight nucleotide UMIs
used in our study have 65 thousand possible sequences, which is
well suitable for cfDNA-based trisomy detection as copy numbers
of cfDNA in 10ml of blood remains <5000.23,24 The same applies
to TAC-seq expression applications if lower RNA concentrations
are used. Alternatively, it is possible to extend UMI sequences in
both detector probes from current 8 to 12 nucleotides, ensuring
16.7 million possible combinations. At the same time we are aware
that introducing significantly longer and random UMI strings into
detector probes may increase the probability of probes self-
pairing and unspecific ligation. However, UMI-related issues such
as ‘‘saturation’’ and replication-caused novel, ‘‘phantom’’ UMIs25
that should be taken into account in assay design and data
analysis.
TAC-seq was designed while keeping in mind the main
prerequisites of genetic testing laboratories—sensitivity, robust-
ness, and cost-efficiency. Sensitivity and molecule counting by
UMI was discussed above. Robustness is ensured by single-tube
protocol to minimize the risk of allelic drop-out. Furthermore, the
approach is dilution-free, meaning that analyzed biomarker
molecules together with ligated detector probes are captured
and identified by sequencing. The latter is crucial in liquid biopsy
samples where each locus is represented only by some thousands
of copies. If ligation-based assay with specific probes is used then
probe hybridization-compatible target cfDNA copy-number
reduces 25% due to the short length of cfDNA (180 bp) as the
locus is not detected if it locates closer than 25 bp to cfDNA
fragmentation site.
TAC-seq detects mRNA biomarkers through oligo-T primed
cDNA synthesis (poly-A selection) that reflects the analysis of
active transcriptome. It differs from TempO-Seq4 where recently
described SplintR ligase26 for RNA/DNA hybrid is used to detect
any, even fragmented RNA targets by specific detector oligonu-
cleotides. In addition, SplintR ligase optimum working tempera-
ture is up to 37 °C that may limit the specificity of formed RNA/
DNA probe complexes prior ligation. In contrast, TAC-seq uses
thermostable Thermus aquaticus (Taq) DNA ligase27 that enables
specific hybridization and ligation at temperature above 45 °C.
Based on this property of Taq DNA ligase, we have carried out first
specific probe-target hybridization at 60 °C and thereafter
introduced ligase to join the proximity annealed strands at the
same temperature.
As sequencing contributes to the majority of the NGS cost, it is
critical to apply library preparation that supports low-coverage
sequencing in routine NGS clinical applications. Cost-effectiveness
of TAC-seq is ensured by off-the-shelf reagents and the usage of
common instruments in genomic laboratory, such as standard
thermocycler and benchtop NGS sequencer. The running cost of
TAC-seq is only a fraction of the cost for commonly used NGS
applications like whole-genome sequencing for NIPT or RNA-seq
for mRNA and miRNA analysis. Set-up cost of TAC-seq depends on
number of studied loci due to the need of specific detector
oligonucleotides (Supplementary Fig. 10). Consumables and their
Fig. 2 Comparison of the overall predictions for mRNA TAC-seq assay. a Principal component analysis of the full transcriptome RNA-seq, high-
coverage TAC-seq and low-coverage TAC-seq of ten endometrial samples. The first principal component (PC1) describes most of the sample
variability and correlates most with the receptivity status. Blue dots represent pre-receptive and red dots receptive human endometrial
samples. One separate pre-receptive sample (indicated with an asterisk) represents the same sample that clusters differently in the heatmap
analysis (below) and is, therefore, a potential biological outlier. b Heatmaps of the full transcriptome RNA-seq, high-coverage-, and low-
coverage TAC-seq show the sensitivity to distinguish different endometrial samples according to their receptivity. One pre-receptive sample
(indicated with an asterisk) shares the expression profile and clusters together with receptive samples in all three comparisons. Pre-receptive
samples are labeled blue and receptive red. Detailed heatmaps are presented in Supplementary Fig. 3 together with housekeeping genes that
demonstrate a lack of fluctuation of the pre-receptive and receptive biopsies. High-coverage TAC-seq data are presented at UMI= 2 and low-
coverage data at UMI= 1 on PCA and heatmaps. Higher UMI thresholds in both high- and low-coverage approaches left low-expressed
biomarker genes, like APOD, EDN3 etc without reads, according to Supplementary Fig. 4. The data are plotted as row-wise scaled log-
transformed counts per million (CPM) values. The samples are hierarchically clustered column-wise using Pearson correlation. The genes are
ordered row-wise according to the RNA-seq clustering results using Euclidean distance. Fewer genes are found expressed with a low-coverage
compared to RNA-seq and high-coverage TAC-seq
Fig. 3 TAC-seq miRNA assay performance. Correlation plots of four
miRNA sample technical replicates using TAC-seq assay at UMI= 4.
miRNA sample 1 is on the left hand and has two replicates, one
plotted on the x-axis and the other on the y-axis. The same with
miRNA sample 2 on the right hand
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approximate prices are listed in Supplementary Table 2 and
explained in Methods. Based on our in-house library preparation
and sequencing, the total reagent cost for miRNA profiling and
cfDNA analysis is less than 30 EUR per sample and 26–40 EUR per
sample for mRNA biomarker analysis, depending on the sequen-
cing depth. Therefore, TAC-seq has the potential to become a
cost-effective alternative for routine NIPT after clinical studies or
for detecting the levels of transcriptome biomarkers.
TAC-seq probe specificity is ensured by 54-bp-long region on
mRNA and gDNA. We developed automated mRNA probe design
software (http://nipt.ut.ee/design/) without restrictions in usage
and described in Supplementary Methods) that automates probe
design procedure and provides highly specific oligonucleotide
sequences with common motifs that are ready for synthesize.
Probe design for miRNA molecules is even more straightforward
and does not require special software (see Supplementary Fig. 6).
Another simplification that makes NGS as a choice of detection
method is user-friendly data analysis. Small-scale NGS data
analysis does not demand powerful computing resources. For
this, we provide user-friendly personal computer software for
small-scale TAC-seq data analysis and open-source code for
intense analysis (link in Methods). The NGS ‘‘big data’’ limitation
has been overcome by simple analysis pipeline. Most resource-
demanding raw data processing after sequencing is done by
Illumina cloud-computing environment. Following TAC-seq analy-
sis is based on text-file manipulations eliminating the need of
sequencing read mapping, making it possible to perform NGS
analysis in personal computer (see details on Methods).
Applied UMI threshold depends on the type of application and
sequencing depth. cfDNA analysis bases on the expectation that
all studied loci are represented in relatively similar copy-number. If
number of PCR cycles is optimized to avoid excess amplification,
we recommend to use UMI= 1 or UMI= 2 threshold (Fig. 4).
Transcriptome biomarker analysis is faced to diversity in original
molecule counts (Supplementary Fig. 4). The differences in
transcriptome determine optimal UMI threshold according to
lowly expressed molecules. Too stringent threshold filters out
lowly expressed biomarkers.
In conclusion, we have developed a highly sensitive and parallel
method to count accurately the number of nucleic acid biomarker
molecules in studied samples. Our proof-of-principle study
demonstrates that TAC-seq has similar sensitivity to golden
standard RNA-seq method in case of mRNA and miRNA
application, and can successfully detect the excess of cfDNA
molecules (indicative of chromosomal trisomy) in cfDNA-like
material. TAC-seq is automation-compatible method that is
designed to overcome ligation- and NGS-based limitations in
genetic testing laboratory. Although all presented applications
need careful clinical validations before they can be utilized, the
described method is the base for further specialization and
optimization to provide advanced DNA and RNA biomarker
analysis tools and thereby improve reach and quality of
corresponding research and healthcare applications.
Fig. 4 Trisomy detection under in vitro conditions. Boxplots over applied UMI thresholds of normalized molecule counts (y-axis) of trisomy
TAC-seq experiments indicates a positive correlation between the trisomy factor (x-axis, trisomic cell proportion) and chr21 counts.
Experiment 1, upper four plots, involved 114 loci along chr2 and chr21. One biological replica is depicted. Experiment 2, lower four plots at
various UMI thresholds, involved extended TAC-seq probe set (in total 224 probes) along chr2, chr3, and chr21. The red asterisks indicate
significant reference chromosome(s) and chr21 read-count-based differences between studied samples (p < 0.05, one-tailed Welch’s t-test)
H. Teder et al.
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METHODS
Studied samples
This study was approved by the Research Ethics Committee of the
University of Tartu (246/T-21 and 221/M-31). Endometrial biopsies for RNA
assays were collected from healthy volunteers and written informed
consent was obtained from all participants. Genomic DNAs from GM01359
(47,XY, +18) and GM04616 (47,XX, +21) cell lines (NIGMS Human Genetic
Cell Repository, Coriell Institute of Medical Research) were extracted using
the DNeasy Blood and Tissue kit (Qiagen). To mimic cfDNA, genomic DNA
was fragmented to 150–200 bp using Covaris M220 Focused-ultrasonicator
(Thermo Fisher).
Detail description of biomarker selection, TAC-seq probe design, library
preparation protocols, and TAC-seq sequencing are described in Supple-
mentary Methods.
TAC-seq data analysis
ERCC spike-in reads were trimmed to construct length of 88-bp and
demultiplexed by barcodes (6-bp) allowing 1 mismatch. Demultiplexed
reads were further trimmed to length of 62-bp and 4-bp of UMI at the end
of the read was inserted after 4-bp of the UMI at the start of the read.
Reads with UMI that contained unallocated nucleotides, were discarded.
Resulting reads per sample were demultiplexed again using target regions
of the genes (54-bp) allowing up to five mismatches. Total read counts,
unique molecule counts and Pearson and Spearman correlations were
calculated at different UMI thresholds. Due to the fact that Pearson
method assumes linear correlation and, therefore, resulted in insensitive
correlations at high UMI thresholds, we chose Spearman correlation as it
proved to work correctly in case of very high and very low molecule
concentrations.
Gene expression reads were processed as described above. To reduce
potential sequencing error accumulating at UMI motif, only reads
appearing at least twice were counted as unique molecules (UMI= 2).
Each sample was normalized to CPM using edgeR (version 3.18.1) package
in R (version 3.4.1) and log-transformed using the log10 (CPM+ 1)
transformation to reduce skewness. In addition to biomarker genes, both
high- and low-coverage TAC-seq libraries included spike-in molecules.
Furthermore, the low-coverage library included eight housekeeping genes,
which were taken into account in CPM normalization. The normalization
procedure was based on the published formula that was further adjusted
for read-count data.
Genomic DNA sequencing data quality control and pre-processing were
performed as described above. Loci that were 1.5 interquartile ranges
(IQRs) below the first quartile or above the third quartile were called as
outliers and removed. As we constantly detected slightly higher molecule
counts in chr2 compared to chr21 in euploid samples, chromosome-
specific molecule counts were applied. For that, mean molecule counts of
chr2 and chr21 (~1.081 at UMI threshold 2) using the euploid samples were
calculated and used for normalization. User-friendly software was
developed to enable TAC-seq data processing in end-user’s personal
computer or in Linux environment.
Code availability
Open-source software with installation instructions are available at https://
github.com/cchtEE/TAC-seq-data analysis and shown schematically in
Supplementary Fig. 2.
Set-up and running cost of TAC-seq
Targeted assay set-up needs two specific probe oligonucleotides for mRNA
and cfDNA analysis. The price we got was 27 EUR per detector pair,
resulting in 800 EUR in total for 30 loci analysis, for example
(Supplementary Fig. 10a). miRNA detection needs only one non-
phosphorylated specific detector per molecule of interest (Supplementary
Fig. 6), lowering the set-up cost to 200 EUR in case of 30 loci. Reagent
costs, using off-the-shelf consumables, show that cDNA synthesis for
mRNA assay is 0.6 EUR per entire sample that is more cost-effective than
miRNA cDNA synthesis (3.2 EUR/sample) that needs more manipulations.
Following ligation, purification and quality control cost 5.4 EUR for mRNA,
miRNA, and cfDNA applications (Supplementary Table 2). Sequencing
contributes majority of the analysis reagent price, being in the range of
20–34 EUR per sample, depending on the application and sequencing
depth (Supplementary Fig. 10b). Based on our in-house library preparation
and sequencing protocol, the total reagent cost for miRNA profiling and
cell-free DNA analysis is <30 EUR per sample and 26–40 EUR per sample for
mRNA biomarker analysis.
DATA AVAILABILITY
Supplementary sequencing data are available in Gene Expression Omnibus database
under accession codes GSE98386 and GSE110110, and in Sequence Read Achieve
under accession code SRP132266.
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